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To establish whether one can build a mortality prediction model for COVID-19 patients
based solely on demographics and comorbidity data that outperforms age alone. Such a
model could be a precursor to implementing smart lockdowns and vaccine distribution
strategies.
Methods
The training cohort comprised 2337 COVID-19 inpatients from nine hospitals in The Nether-
lands. The clinical outcome was death within 21 days of being discharged. The features
were derived from electronic health records collected during admission. Three feature selec-
tion methods were used: LASSO, univariate using a novel metric, and pairwise (age being
half of each pair). 478 patients from Belgium were used to test the model. All modeling
attempts were compared against an age-only model.
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Results
In the training cohort, the mortality group’s median age was 77 years (interquartile range =
70–83), higher than the non-mortality group (median = 65, IQR = 55–75). The incidence of
former/active smokers, male gender, hypertension, diabetes, dementia, cancer, chronic
obstructive pulmonary disease, chronic cardiac disease, chronic neurological disease, and
chronic kidney disease was higher in the mortality group. All stated differences were statisti-
cally significant after Bonferroni correction. LASSO selected eight features, novel univariate
chose five, and pairwise chose none. No model was able to surpass an age-only model in
the external validation set, where age had an AUC of 0.85 and a balanced accuracy of 0.77.
Conclusion
When applied to an external validation set, we found that an age-only mortality model out-
performed all modeling attempts (curated on www.covid19risk.ai) using three feature selec-
tion methods on 22 demographic and comorbid features.
Introduction
Discovered in December 2019, the outbreak of COVID-19 is the most devastating pandemic
in a century [1]. As of March 7, 2021, more than 116 million people have been infected glob-
ally, and about 2.6 million COVID-19 patients have died [2]. This pandemic has not only
greatly threatened the lives and health of the world’s population but has also restricted global
trade and economic development [3].
COVID-19 is a new disease caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) which targets the angiotensin-converting enzyme 2 (ACE-2), with symptoms
ranging from mild to critical [4]. The patients with a more severe illness are often more diffi-
cult to treat and have poor prognosis, including death [5]. While researchers have made
unprecedentedly rapid progress in understanding the occurrence, progression, and treatment
of the disease [6–8], it is still urgent to identify the risk factors for severe illness from COVID-
19 and to protect the most vulnerable people. Previous studies have reported that older age,
male gender, smoking and other conditions such as hypertension, diabetes, obesity, and
chronic lung disease are the risk factors for severe illness or death [9–15]. However, to our
knowledge, there are no publications that have attempted to predict disease severity or patient
mortality using only such risk factors and then successfully validated such a model on an exter-
nal cohort.
There is great value in having a predictive model for COVID-19 mortality that is based
solely on demographics and underlying conditions, and which does not require blood test
results or even initial symptoms. There are many beneficiaries from such a model. At the indi-
vidual level, this can facilitate telemedicine for patients that have tested positive as well as
inform citizens who have yet to contract COVID-19 of their potential risk, allowing them to
take precautionary measures. At the government level, it can be used to implement smart lock-
down approaches. As of March 2021, there are several vaccines that have obtained regulatory
approval from various national agencies. However, given that the global population needs to
be vaccinated against COVID-19, and the manufacturing limitations meaning that it is
unlikely that the entire population can be inoculated in 2021, it is crucial that the available
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vaccines are distributed so as to have the maximum positive impact on public health. Such a
predictive model would be a valuable addition to vaccine distribution decisions.
The aim of this study was to investigate potential risk factors and to develop prediction
models for mortality based on demographics and underlying conditions and compare its per-
formance to age alone. Ideally, a model would be desirable that can be applied to people who
have not yet contracted COVID-19, so they can assess their risk level and take additional pre-
cautions compared to what is mandated by the government, e.g., not using public transporta-
tion, and doing all shopping online. This can also be applied by the authorities for rational
prioritization of vaccination. We would also like a model that can be applied to people who
have a positive test of COVID-19, and are undergoing a remote consultation with a physician
to decide if they should visit the hospital. From a practical standpoint, however, such unbiased
data is difficult to obtain, and thus our goal for this paper was to perform a proof-of-principle
analysis using inpatient data from multiple European centers; the same analysis approach can
then be applied to unbiased data, when available.
Methods
Study design and participants
The institutional ethics board of Amsterdam University Medical Center, The Netherlands,
Maastricht University Medical Center, The Netherlands, and Liege University Hospital Cen-
tre, Belgium approved this retrospective study; the written informed consent was waived. All
inpatients with confirmed COVID-19 from the nine Dutch hospitals (www.covidpredict.org)
and consecutively enrolled from March 1, 2020 to July 1, 2020 comprised the training cohort.
The contemporaneous data from Liege University Hospital was retrospectively collected for
external validation. Patients with incomplete records (with more than half missing features),
or under the age of 18 years, or lost to follow-up were excluded. This study can be classified as
Type 3 (external validation) according to TRIPOD statement [16]. A confirmed case with
COVID-19 was defined as a positive result of high-throughput sequencing or real-time
reverse-transcriptase polymerase-chain-reaction assay for nasal and pharyngeal swab speci-
mens. The end-point was death, and the follow-up period was 21 days after being discharged.
Data collection
The data was derived from electronic health records collected during admission, including age,
sex, smoking history, healthcare worker, alcohol use disorder, pregnancy, hypertension, diabetes,
cancer, rheumatic diseases, autoimmune disorder, dementia, chronic obstructive pulmonary dis-
ease (COPD), asthma, chronic cardiac disease (CCD), chronic hematologic disease (CHD),
chronic neurological disease (CND), chronic kidney disease (CKD), chronic liver disease (CLD),
cachexia, Acquired Immune Deficiency Syndrome (AIDS), and organ transplant. The data was
retrieved during July 12–16, 2020. Smoking history was categorized as current smokers, former
smokers, and never smokers. Chronic cardiac disease included coronary artery disease, heart
attack, and congenital heart disease. Chronic neurological disease contained Alzheimer’s disease,
Parkinson’s disease, dystonia, Lou Gehrig’s disease, Huntington’s disease, neuromuscular dis-
ease, multiple sclerosis, and epilepsy. Chronic kidney disease was defined as glomerular filtration
value< 60. Chronic liver disease comprised chronic hepatitis and liver cirrhosis.
Statistical analysis
Missing data was imputed by using the missForest method based on the Random Forest (RF)
algorithm [17]. Continuous data were summarized as median with interquartile range and
PLOS ONE Predicting COVID-19 mortality in a European cohort using only demographic and comorbidity data
PLOS ONE | https://doi.org/10.1371/journal.pone.0249920 April 15, 2021 3 / 15
categorical variables as frequency (%). Differences between the mortality and non-mortality
groups were tested using the Mann-Whitney test for continuous data and χ2 test or Fisher’s
exact test for categorical data. A two-sided p-value of less than 0.002 was regarded as statisti-
cally significant, chosen by applying a Bonferroni correction to the standard value of 0.05 to
account for the 22 features being explored. This analysis was performed by using R for Win-
dows (version 3.5.3). In addition, three feature selection approaches were used for predictive
modeling, as described below.
LASSO-based feature selection. The least absolute shrinkage and selection operator
(LASSO) with five-fold cross validation was used to select the optimal subset of predictive fea-
tures. To check whether overtraining occurred in the LASSO approach, the training cohort
was randomly spit into training and internal validation subsets (4:1). A logistic regression
model and visual nomogram were built from the selected features. No imbalance adjustment
was performed in the training cohort. Instead, the optimal classification threshold was chosen
to maximize Youden’s J statistic. This threshold was also applied to the external validation set.
The measures of model performance included the area under the receiver operating character-
istic (ROC) curve (AUC), sensitivity, specificity, and balanced accuracy. This analysis was per-
formed by using R for Windows (version 3.5.3). This model was compared against an age-only
linear discriminant (LD) model in the external validation set.
Univariate feature selection using a novel metric. As described above, when deciding
whether a feature differs between the mortality and non-mortality groups, the p-values of the
relevant statistical tests were used. However, the fact that a feature differs between two groups
does not necessarily mean that it can be used to discriminate between the two groups. To illus-
trate the limitation of a powerful binary feature (i.e., one with a large odds ratio) in terms of
predictive modeling, let us consider two simple numerical examples. First, let us introduce
some notation (exposed and non-exposed refer to the presence or absence of a risk factor) to
define four categories of patients: dead and non-exposed (DN), healthy and non-exposed
(HN), dead and exposed (DE), healthy and exposed (HE). The odds ratio is then given by: OR
= (DE/HE)/(DN/HN)
In example 1, DE = 140, HE = 60, DN = 60, HN = 140. In this case, the exposed group (140
+60) and non-exposed group (60+140) both have the same size. An example of such a risk fac-
tor could be male gender. The odds ratio is 5.44, and AUC is 0.7. If we were to build a linear
discriminant classifier using just this feature, it would classify all the exposed patients as dead,
and all the non-exposed patients as healthy. Thus, the sensitivity would be 140/(140+60) = 0.7,
the specificity would be 140/(140+60) = 0.7, and the balanced accuracy would be 0.7.
In example 2, DE = 7, HE = 3, DN = 60, HN = 140. In this case, the exposed group (7+3) is
20 times smaller than the non-exposed group (60+140). An example of such a risk factor could
be chronic liver disease. The odds ratio is still 5.44, but the AUC is only 0.54. If we were to
build a linear discriminant classifier using just this feature, it would classify all the exposed
patients as diseased, and all the non-exposed patients as healthy. Thus, the sensitivity would be
7/(7+60) = 0.10, the specificity would be 140/(140+3) = 0.98, and the balanced accuracy would
be 0.54.
One way to decide whether a feature is good at distinguishing between two groups is to
check its AUC. Of course, other metrics like sensitivity, specificity, positive predictive value,
and the negative predictive value also matter, but if the AUC is no better than random, these
other metrics will be poor as well. Checking that the AUC is above 0.5 is not sufficient to deter-
mine if a feature is useful, as higher values of AUC can happen randomly, and this becomes
more likely for small training cohorts or when a large number of features are being
considered.
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The DeLong test can be used to determine if the AUC of a feature is better than another fea-
ture, a special case of which is a random feature. This fact was used to devise a novel metric for
univariate feature selection. 1000 features were generated randomly as follows: for a training
cohort of size N, each feature was a set of N numbers drawn randomly between 0 and 1 from a
uniform distribution. The DeLong test was then performed (requiring p<0.05) to decide if the
real feature under consideration was better than the randomly generated feature. We required
that the real feature be better than a randomly generated feature at least 950 out of 1000 times,
which we denoted as pDeLong < 0.05. The features selected in this way were combined using a
RF (200 trees, with the maximum number of decisions per tree limited to 3 to avoid overtrain-
ing). This model was compared against an age-only LD model in the external validation set.
This feature selection method and the next method as well were implemented using MATLAB
R2019a (MathWorks, Natick, MA).
Pairwise feature selection. As mentioned previously, 22 features were considered for
inclusion, of which age was the only one known to be a powerful discriminator. In the pairwise
approach, we built machine learning classifiers with just a pair of features at a time, where age
was always part of each pair (e.g., age + sex, age + smoking history). Thus, there were 21 pairs
considered (22 features–age). Two classifiers were used: LD (chosen for its simplicity) and RF
(200 trees, with the maximum number of decision per tree limited to 5 to avoid overtraining).
If either of these classifiers performed better than age alone, then the feature would be selected.
To determine performance improvement, both AUC and balanced accuracy would need to be
higher by at least 0.01 for the pairwise model compared to age alone. The reason for introduc-
ing this requirement was that when the training cohort is sufficiently large (over 1000
patients), even an improvement smaller than 0.01 in AUC could be statistically significant (i.e.,
DeLong test p-value < 0.05), and such a difference would have no impact in a real-world set-
ting. All features selected in this way would then be combined using a RF. This model, if cre-
ated despite the rigorous feature selection process (more restrictive than the first two feature
selection methods), would then be compared against an age-only LD model in the external val-
idation set.
Results
The characteristics of demography and complications
2929 COVID-19 patients were searched, of whom 114 patients were excluded from this study
due to more than half missing variables (n = 52), being under the age of 18 (n = 10), and being
lost to follow-up (n = 52) (Fig 1). Of the 2337 included COVID-19 patients from the Nether-
lands, 568 (24.3%) patients died. The characteristics of demography and complications are
summarized in Table 1. Of the 478 included COVID-19 patients from Belgium, 41 (8.6%)
patients died.
Differences in groups
After imputation of missing values, the median age of mortality group was 77 years (interquar-
tile range, 70–83), which was older than non-mortality group with a median age of 65 years
(interquartile range, 55–75, p< 0.001). Smoking history showed significant difference between
mortality and non-mortality group (p< 0.001). The proportion of healthcare workers in mor-
tality group was lower than in non-mortality group (p< 0.001). The incidence of male gender
(p< 0.001), hypertension (p< 0.001), diabetes (p< 0.001), dementia (p< 0.001), cancer
(p = 0.001), COPD (p = 0.002), CCD (p < 0.001), CND (p< 0.001), and CKD (p< 0.001) in
mortality group was higher than in non-mortality group. The detailed demographic and
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complication characteristics of the training cohort are shown in Table 2. A similar table for the
external validation cohort can be found in Table A3 in S1 Appendix.
LASSO-based feature selection
LASSO selected eight features including age, sex, smoking history, diabetes, dementia, cancer,
CND, and CLD. Using these features, in the training set, the model had an AUC of 0.76 (95%
CI: 0.74–0.78) with a sensitivity of 0.69, a specificity of 0.70, and a balanced accuracy of 0.70.
In the internal validation dataset, the AUC was 0.76 (95% CI: 0.72–0.81), with a sensitivity of
0.75, a specificity of 0.68, and a balanced accuracy of 0.71. In the external validation set, the
AUC was 0.84 (95% CI: 0.79–0.89), with a sensitivity of 0.61, a specificity of 0.83, and a bal-
anced accuracy of 0.72. The nomogram is shown in Fig A1 in S1 Appendix. By comparison, an
age-only LD model performed as follows in the external validation set: AUC = 0.85, sensitiv-
ity = 0.71, specificity = 0.84, balanced accuracy = 0.77; thus, the LASSO model did not perform
better than the age-only model.
Univariate feature selection
Table 3 shows the results of the univariate feature selection process. It includes AUC and pDe-
Long. For binary features, it also includes odds ratio and the p-value of the Fisher test. Although
the Fisher test p-values were already mentioned in Table 2, they are included in Table 3 to
show how different they are compared to our novel metric. Five features passed selection: age,
smoking history, hypertension, diabetes, and CCD. The RF model based on these features per-
formed as follows on the training cohort: AUC = 0.76, sensitivity = 0.73, specificity = 0.67, bal-
anced accuracy = 0.70. On the external validation set, the results were: AUC = 0.85,
sensitivity = 0.68, specificity = 0.84, balanced accuracy = 0.76. Thus, this model did not surpass
the age-only model.
Fig 1. Flowchart of patient selection.
https://doi.org/10.1371/journal.pone.0249920.g001
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Pairwise feature selection
Table 4 shows the results of pairwise feature selection. It shows AUC and balanced accuracy
for each feature pair (i.e., age combined with one of the other 21 features), with two classifiers
(LD and RF). No pair showed an improvement in AUC and balanced accuracy of at least 0.01,
and therefore no feature passed selection. Thus, no predictive model could be built.
Discussion
This multicenter study investigated the risk factors of mortality for the patients with COVID-
19. Age, sex, smoking history, diabetes, dementia, cancer, chronic neurological disease, and
chronic liver disease were selected by our LASSO feature selection.
Age is a recognized risk factor for the COVID-19 from current evidence [18]. Here, we
found that the median age of mortality group was 77.0 years, which was significantly older
than non-mortality group with a median age of 65.0 years. Our study found that males have a
Table 1. Participant characteristics with missing values of COVID-19 patients (training cohort).
Characteristic Missing Values, n (%) Counts, n (%)
Died patients 0 568 (24.3)
Demography
Age 0 Mean: 66.8 ± 14.4 y
Male 0 1471 (62.9)
Smoking 621 (26.6)
Never smoking 861 (36.8)
Former smoker 738 (31.6)
Current smoker 117 (5.0)
Healthcare worker 104 (4.5) 98 (4.2)
Alcohol use disorder 453 (19.4) 50 (2.1)
Pregnancy 0 11 (0.5)
Complications
Hypertension 7 (0.3) 1079 (46.2)
Diabetes 0 609 (26.1)
Rheumatic diseases 1 (0.04) 258 (11.0)
Autoimmune disorder 22 (0.9) 187 (8.0)
Dementia 13 (0.6) 99 (4.2)
Cancer 13 (0.6) 164 (7.0)
COPD 4 (0.2) 437 (18.7)
Asthma 7 (0.3) 226 (9.7)
CHD 3 (0.1) 87 (3.7)
CCD 3 (0.1) 706 (30.2)
CND 4 (0.2) 315 (13.5)
CLD 0 110 (4.7)
CKD 3 (0.1) 268 (11.5)
AIDS 4 (0.2) 10 (0.4)
Cachexia 0 33 (1.4)
Organ transplant 0 33 (1.4)
COPD, chronic obstructive pulmonary disease; CHD, chronic hematologic disease; CCD, chronic cardiac disease;
CND, chronic neurological disease; CLD, chronic liver disease; CKD, chronic kidney disease; AIDS, Acquired
Immune Deficiency Syndrome.
https://doi.org/10.1371/journal.pone.0249920.t001
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higher probability of dying when infected COVID-19, consistent with prior publications.
Some researchers speculated this is due to higher smoking rates among males [19–21]. How-
ever, our predictive model includes both sex and smoking history, indicating that both of these
play a contributing role and the dependence on sex cannot be explained away as an effect of
smoking history.
Recent studies have reported hypertension, and diabetes were risk factors for the mortality
of COVID-19 [22–24]. In this study, we found that the existence of hypertension and diabetes
were more common on the mortality group. It is worth noting that hypertension and diabetes
have a common association with increased ACE-2 receptor, and enhanced expression of ACE-
2 receptor in adipose tissue has been found in recent publication [25]. However, it is unclear
whether ACE-2-stimulating drugs or the complication itself increased risk of death for hyper-
tension and diabetes. Patients with rheumatic diseases are at an increased risk of infection
[26]. In this study, we found that the mortality group had more patients with rheumatic dis-
eases than non-mortality group (14.1% vs 10.1%). However, this was not statistically signifi-
cant after application of the severe Bonferroni correction for multiple hypothesis testing.
Epidemiological studies have shown a significant association between poor COVID-19 out-
comes and dementia [27]. A study with 627 COVID-19 patients from Italy reported that the
mortality rate was significantly higher in ones with dementia than the ones without [28]. Here,
Table 2. Participant characteristics of mortality and non-mortality groups for COVID-19 patients after missing value imputation (training cohort).
Non-mortality (n = 1769) Mortality (n = 568) p-value
Age (median [IQR]) 65 [55, 75] 77 [70, 83] <0.001
Sex, male (%) 1078 (60.9) 393 (69.2) <0.001
Smoking (%) <0.001
Never smoking 1004 (56.8) 250 (44.0)
Former smoker 635 (35.9) 263 (46.3)
Current smoker 130 (7.3) 55 (9.7)
Healthcare worker (%) 112 (6.3) 6 (1.1) <0.001
Alcohol use disorder (%) 61 (3.4) 27 (4.8) 0.164
Pregnancy (%) 11 (0.6) 0 (0.0) 0.076
Hypertension (%) 761 (43.0) 323 (56.9) <0.001
Diabetes (%) 403 (22.8) 206 (36.3) <0.001
Rheumatic diseases (%) 178 (10.1) 80 (14.1) 0.009
Autoimmune disorder (%) 147 (8.3) 43 (7.6) 0.659
Dementia (%) 47 (2.7) 61 (10.7) <0.001
Cancer (%) 109 (6.2) 60 (10.6) 0.001
COPD (%) 306 (17.3) 132 (23.2) 0.002
Asthma (%) 183 (10.3) 44 (7.7) 0.073
CHD (%) 64 (3.6) 23 (4.0) 0.612
CCD (%) 461 (26.1) 247 (43.5) <0.001
CND (%) 199 (11.2) 117 (20.6) <0.001
CLD (%) 75 (4.2) 35(6.2) 0.068
CKD (%) 166 (9.4) 102 (18.0) <0.001
AIDS (%) 10 (0.6) 0 (0.0) 0.131
Cachexia (%) 27 (1.5) 6 (1.1) 0.54
Organ transplant (%) 27 (1.5) 6 (1.1) 0.54
COPD, chronic obstructive pulmonary disease; CHD, chronic hematologic disease; CCD, chronic cardiac disease; CND, chronic neurological disease; CLD, chronic
liver disease; CKD, chronic kidney disease; AIDS, Acquired Immune Deficiency Syndrome; IQR, interquartile range.
https://doi.org/10.1371/journal.pone.0249920.t002
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the dementia rate of mortality group was significantly higher than non-mortality group (10.7%
vs. 2.7%). A previous study concluded that cancer treatments such as surgery, radiotherapy,
and chemotherapy may weaken the immune system, which is detrimental for people if infected
with COVID-19 [29]. Our findings were in agreement, as cancer rates in the mortality group
were significantly higher than in the non-mortality group (10.6% vs 6.2%).
Furthermore, we found that several chronic diseases in lung, heart, kidney, and nervous
system might increase the risk of mortality for COVID-19. The possible explanation is that
these diseases have higher expression levels of ACE-2, which is associated with increased mor-
tality of COVID-19 [30–32]. Current evidence indicated SARS-CoV-2 might have direct or
indirect negative effect on the circulatory system such as abnormal clotting and vascular
inflammation, though the detailed mechanism is still unclear [33]. Although the expression
level of ACE-2 is low in central nervous system, some studies have put forward the neuro-inva-
sive potentiality of SARS-CoV-2 that may potentially cause acute respiratory failure for
patients with chronic neurological disease [34]. This may explain why chronic neurological
disease is a risk factor for mortality caused by COVID-19.
Unlike previous published studies [35–37], our model used only the demographics and
comorbidities of COVID-19 patients without any laboratory tests or medical images or even
symptoms to predict the mortality. There was a recent publication [38] to predict in-hospital
morality of COVID-19 patients using Italian data. Fine and Gray competing risks multivariate
model (with discharge as a competing event) was used to develop a prediction rule for in-
Table 3. Results of univariate feature selection in the training cohort using the novel metric pDeLong.
AUC pDeLong OR p-value
Age 0.74 <0.001 - -
Sex 0.54 0.317 1.44 <0.001
Smoking History 0.56 0.022 - -
Healthcare worker 0.53 0.555 0.16 <0.001
Alcohol use disorder 0.51 0.926 1.40 0.164
Pregnancy 0.50 0.947 0.00 0.076
Hypertension 0.57 0.010 1.75 <0.001
Diabetes 0.57 0.012 1.93 <0.001
Rheumatic diseases 0.52 0.805 1.47 0.009
Autoimmune disorder 0.50 0.970 0.90 0.659
Dementia 0.54 0.234 4.41 <0.001
Cancer 0.52 0.745 1.80 0.001
COPD 0.53 0.616 1.45 0.002
Asthma 0.51 0.893 0.73 0.073
CHD 0.50 0.949 1.12 0.612
CCD 0.59 <0.001 2.18 <0.001
CND 0.55 0.160 2.05 <0.001
CLD 0.51 0.904 1.48 0.068
CKD 0.54 0.227 2.11 <0.001
AIDS 0.50 0.946 0.00 0.131
Cachexia 0.50 0.958 0.69 0.54
Organ transplant 0.50 0.957 0.69 0.54
Selected features are in bold. COPD, chronic obstructive pulmonary disease; CHD, chronic hematologic disease; CCD, chronic cardiac disease; CND, chronic
neurological disease; CLD, chronic liver disease; CKD, chronic kidney disease; AIDS, Acquired Immune Deficiency Syndrome; AUC, area under the Receiver Operating
Characteristic curve; OR, odds ratio.
https://doi.org/10.1371/journal.pone.0249920.t003
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hospital mortality. However, their model included duration of symptoms before hospital
admission and lactate dehydrogenase levels at hospital admissions, and thus cannot be applied
for people who have yet to contract COVID-19. The aim of our approach was to find which
features are likely to be most important when identifying patients with a high risk of mortality
even before the patient has become symptomatic. However, in terms of model-building, we
found that an age-only model could not be outperformed by any of our models in the external
validation set. One can argue that if there is no overtraining, a model that performs better than
an age-only model in just the training cohort may still be useful, since the performance in the
external validation set is affected by factors such as differences in cohort characteristics and
admission/treatment policy differences between The Netherlands and Belgium. The age-only
model had an AUC of 0.74 in the training cohort (Table 3); compared to the LASSO model,
which had an AUC of 0.76, it is slightly lower, but not enough to be clinically significant, and
therefore not enough to justify the increase in model complexity (eight features vs one).
Of the 22 features we considered for model building, only two (age and smoking history)
were not binary. Table 3 reveals that most binary features had modest odds ratios (around 2 or
lower), and for the two exceptions (healthcare worker and dementia), the incidence of these
factors within the cohort was low (about 5%). Thus, it is unsurprising that none of them had a
high AUC (>0.6). When collecting data for a predictive model, whenever possible, it is better
Table 4. Results of pair-wise feature selection in the training cohort.
AUC (LD) BA (LD) AUC (RF) BA (RF)
Age 0.742 0.685 0.753 0.694
Sex 0.748 0.684 0.757 0.693
Smoking History 0.745 0.684 0.754 0.688
Healthcare worker 0.743 0.685 0.754 0.692
Alcohol use disorder 0.743 0.686 0.754 0.690
Pregnancy 0.742 0.685 0.754 0.692
Hypertension 0.743 0.689 0.754 0.698
Diabetes 0.748 0.691 0.757 0.698
Rheumatic diseases 0.742 0.686 0.755 0.697
Autoimmune disorder 0.743 0.687 0.755 0.696
Dementia 0.747 0.690 0.755 0.690
Cancer 0.743 0.686 0.755 0.687
COPD 0.743 0.688 0.755 0.692
Asthma 0.743 0.686 0.755 0.690
CHD 0.742 0.685 0.753 0.693
CCD 0.741 0.688 0.752 0.690
CND 0.745 0.696 0.759 0.700
CLD 0.743 0.685 0.754 0.688
CKD 0.743 0.686 0.754 0.687
AIDS 0.743 0.686 0.753 0.696
Cachexia 0.744 0.687 0.754 0.694
Organ transplant 0.743 0.686 0.753 0.694
The first row shows the performance of age alone, and subsequent rows show the performance of a pair of features, where age is always one half of the pair, e.g., Sex
means Age + Sex and Diabetes means Age + Diabetes. The third significant figure is included to show minute differences (not statistically significant). COPD, chronic
obstructive pulmonary disease; CHD, chronic hematologic disease; CCD, chronic cardiac disease; CND, chronic neurological disease; CLD, chronic liver disease; CKD,
chronic kidney disease; AIDS, Acquired Immune Deficiency Syndrome; AUC, area under the Receiver Operating Characteristic curve; BA, balanced accuracy; LD,
linear discriminant; RF, random forest.
https://doi.org/10.1371/journal.pone.0249920.t004
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to use ordinal categorical variables (i.e., a scale) or continuous variables rather than convert
them to binary variables. For example, when considering a pre-existing condition like alcohol
use disorder, using a scale (say 0–4, tied to the average alcohol consumption per week) is supe-
rior to a simple binary feature (alcoholic vs not alcoholic). When considering a pre-existing
condition like obesity, using a continuous variable like body mass index (BMI) is superior or a
simple binary (BMI> = 30 vs BMI < 30). The reason is that the decision threshold of the pre-
dictive model can then be tuned based on the training data, whereas for a binary variable, no
such tuning is possible.
The training cohort used in this paper has a large (>90%) overlap with another recent pub-
lication (Ottenhoff et al, [39]). However, that publication predicted mortality using premorbid
and clinical presentation features in conjunction with laboratory and radiology values at
admission. The aim was to achieve the highest possible predictive performance by leveraging
the combination of this multifactorial data, which would then be used for effective patient tri-
age during hospital admission. A secondary aim arose from the Dutch government’s firm
opposition to using an age-based decision rule for ICU care because it is in violation of the
constitution, which states that everyone should be treated equally. To contribute to this discus-
sion, the effect of age on the best performing model was assessed, by retraining the model on
the same feature set, while excluding age as feature. This paper, by sharp contrast, only uses
demographic and comorbid data (since the ultimate aim is to make a predictive model for
uninfected individuals), and tries to establish whether adding features to age benefits predic-
tive performance. The team involved in designing this study and doing the statistical analysis
has no overlap with the Ottenhoff et al publication. Furthermore, this study uses an external
(non-Dutch) test cohort.
This study has certain limitations. The most important shortcoming is the biased nature of
the dataset, since it only includes patients who were admitted to the hospital. However, we
stress that obtaining an unbiased sample while still having the necessary follow-up data is a
huge obstacle. For example, if using a smartphone app to obtain a cohort, it would be enor-
mously challenging to know if a patient died after contracting COVID-19. We acknowledge
that in the general population, comorbidities might be better prognostic factors than what was
observed in our data. Second, the detailed breakdown of complications should be taken into
account in the future studies, when larger datasets are available. This is particularly important
because there is a wide spectrum of severity included under CCD and CND. Third, binary var-
iables were included during data collection, which we argue should be avoided whenever pos-
sible. Fourth, our model was trained on Dutch patients and tested on Belgian patients. While
the two cohorts were quite different (as seen by the drastically different mortality rates of
24.3% vs 8.6%), for a country that is sufficiently different from those included in this study,
e.g., in terms of lifestyle or genetics, it is possible that our findings will not apply. Fifth, our
study did not include BMI, which is now known to be an important risk factor [21, 22]. Unfor-
tunately, due to the retrospective nature of the study, we were limited to only those features
which were recorded by the various institutions in the absence of a well-defined protocol in
the early months of the pandemic. We acknowledge that including BMI could potentially
improve the performance of an age-only model. We have included BMI in the list of features
for our ongoing prospective studies. Finally, RNA viruses can mutate rapidly and that could
have an impact of the risk factor of the disease.
The reader may be surprised that even though Belgium has been reported in the news to
have the highest per-capita mortality rate for COVID-19 in the world, the mortality rate in the
Liege hospital is much lower than in the Dutch hospitals. The per-capita death rates in Belgium
are based on counting deaths in hospitals and care homes, but including deaths in care homes
that are suspected, not confirmed, as Covid-19 cases (i.e., no positive test required). Hence,
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there should not be any expectation of the per-capita mortality rates having any relationship to
the rates observed in this study (which are based on hospital admissions and positive COVID-
19 tests). We believe the driving factor for the difference in mortality rates between the Dutch
and Belgian cohorts is age: the median age in the Dutch cohort was 68 years, whereas for the
Belgian cohort, it was 58 years. Since there was no strictly-defined admission indication for the
Dutch consortium, a comparison with the Belgian hospitalization criteria is not possible.
Conclusions
We found some features of demographics and comorbidities to be significantly associated with
death of COVID-19 patients. For people who have not been infected by COVID-19, a model
based on such features could allow people with a potentially high risk of death to follow a
much stricter set of preventive measures than what is mandated by the government, or even
allow the government to enact a smart lockdown. For people who have been infected by
COVID-19 but have yet to develop symptoms, such a model would help identify at-risk
patients, who would then be encouraged by doctors to visit the hospital. The government
could also use this model to design a vaccine distribution strategy that would maximize the
positive impact on public health with the limited number of vaccines available at a given time.
However, despite our multiple rigorous attempts to create such a model, we were unable to
surpass the predictive performance of age alone in an external validation set. If the goal is to
use a risk factor for predictive modeling, it is essential to mention the predictive performance
of such a feature, including metrics such as AUC, sensitivity, specificity, and balanced accu-
racy. Researchers who are investigating potential risk factors for COVID-19 mortality should
check to see if their findings actually improve predictive performance relative to age alone and
not just state an odds ratio of the feature. While age is a strong prognosticator of mortality in
this analysis, it is not possible to say whether this is due to senescence or due to the strong cor-
relation of age with lifestyle-related comorbidities (e.g., hypertension and diabetes) in such a
study. Future studies that take other biological age metrics into account besides chronological
age are needed to address such questions.
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